The RRs of myocardial infarction, atrial fibrillation, and QTc interval prolongation were similar between the BRAF and MEK inhibitor group and the BRAF inhibitor monotherapy control group (Figure 2). This evidence concerns the gene BRAF and myocardial infarction.